ライフサイエンスコーパス: operational tolerance

1 om mTOR-I therapy in LTRs and achieved > 50% operational tolerance.

2 from mTOR-I therapy in LTR and achieved >50% operational tolerance.

3 plantation in relation to liver function and operational tolerance.

4 loss of grafts after long periods of stable operational tolerance.

5 regulatory T (T(reg)) cells appear to foster operational tolerance.

6 transplantation medicine is the promotion of operational tolerance.

7 eral blood mononuclear cells correlates with operational tolerance.

8 onor islet transplantation with induction of operational tolerance.

9 islets off all immunosuppression, suggesting operational tolerance.

10 a central role of androgens in establishing operational tolerance.

11 merged as potential candidate biomarkers for operational tolerance.

12 of immunosuppression withdrawal to identify operational tolerance.

13 clinical diabetes after 5 years, suggesting operational tolerance.

14 bodies as well as cytokines that can promote operational tolerance.

15 ransplant (LT) patients occasionally achieve operational tolerance.

16 long-term allograft fibrosis and failure of operational tolerance.

17 luating the immune landscape associated with operational tolerance.

18 ction of adenosine may be a key regulator of operational tolerance.

19 ine the utility of a predictive biomarker of operational tolerance.

20 top progression of recurrent PSC and promote operational tolerance.

21 stigate the rationale for the development of operational tolerance across a major histocompatibility

22 pression, this is the first instance of true operational tolerance after complete cessation of immuno

23 The mechanisms underlying operational tolerance after hematopoietic stem cell tran

24 Achieving operational tolerance after liver transplantation remain

25 velop a state of targeted immune quiescence (operational tolerance) against an HLA-mismatched graft,

26 We then compared individuals with operational tolerance and nontolerant recipients at the

27 intensive course of tacrolimus could induce operational tolerance and whether preoperative allopepti

28 inical end points included the durability of operational tolerance, and the incidence, timing, severi

29 The primary end point was operational tolerance at 52 weeks following complete ISW

30 (KLF6, BNC2, CYP1B1) to detect the state of operational tolerance by quantitative PCR.

31 This study provides the first evidence that operational tolerance can protect MHC nonhuman primate i

32 absence of immunosuppression (IS), known as operational tolerance, can be achieved in a small propor

33 Patients with operational tolerance compared with patients without ope

34 sies from patients with spontaneous clinical operational tolerance (COT).

35 IS)-free state [also referred to as clinical operational tolerance (COT)] represents the ultimate goa

36 Our aim was to determine if operational tolerance could be observed in LTR withdrawn

37 Our aim was to determine if operational tolerance could be observed in LTRs withdraw

38 dpoint of the study was the establishment of operational tolerance defined as lack of biochemical, hi

39 CD8+ donor bone marrow cells induced operational tolerance (defined as graft acceptance in th

40 The primary endpoint was the development of operational tolerance, defined as successful immunosuppr

41 The primary efficacy endpoint was operational tolerance, defined by strict biochemical and

42 Although operational tolerance has been achieved in liver and kid

43 of continuing immunosuppression, defined as operational tolerance, has never been described in the c

44 urrent acceptance of the allograft-so-called operational tolerance-has proven elusive.

45 ieved in 22 (27.5%), but only 13 (16.3%) met operational tolerance histologic criteria (10 in arm A;

46 imus, we have been able to induce a state of operational tolerance in a class I-disparate preclinical

47 By presenting the first case report of true operational tolerance in an intestinal transplant patien

48 contribute to transplantation tolerance and operational tolerance in both experimental and clinical

49 have been described to be upregulated during operational tolerance in kidney allograft recipients.

50 We have previously reported operational tolerance in patients receiving human leukoc

51 To identify biomarkers of operational tolerance in pediatric and adult liver trans

52 ranscriptional profiles can be identified in operational tolerance in pediatric and adult recipients

53 possibility to create T(reg) cell-regulated operational tolerance in the absence of complete immune

54 nd a gene expression signature suggestive of operational tolerance in three of four patients.

55 cell-based strategies for the enhancement of operational tolerance in transplantation patients.

56 The operational tolerance induction protocol combined peritr

57 nal tolerance compared with patients without operational tolerance initiated immunosuppression withdr

58 The concept of operational tolerance is more meaningful in the clinical

59 Operational tolerance is not a permanent state, and cont

60 ection of the primary graft, suggesting that operational tolerance is not systemic but restricted to

61 hieved, but from the patient's point of view operational tolerance is the goal whereby, after a short

62 The term "operational tolerance" is used to indicate durable survi

63 ciated with long-term allograft survival and operational tolerance, memory B cells have been linked t

64 In this operational tolerance model, all immunosuppression was d

65 her than a deletional process underlies this operational tolerance model.

66 Although operational tolerance occurred following aHSCT, the high

67 Increased serum HLA-G levels track with operational tolerance of liver grafts and support favora

68 Operational tolerance (OT) after kidney transplantation

69 osuppression withdrawal (ISW), also known as operational tolerance (OT), can occur spontaneously afte

70 lly identified in a patient cohort with high operational tolerance prevalence, consisted of a 5-gene

71 ng-term allograft survival, and induction of operational tolerance remain major unmet needs in organ

72 le of Foxp3(+) regulatory T cells (Tregs) in operational tolerance remains elusive, as initial result

73 patients showed the Immune Tolerance Network operational tolerance signature.CONCLUSIONMIC administra

74 ver transplantation resulting in spontaneous operational tolerance (SOT), although the underlying mec

75 myeloid or lymphoid dendritic cells induces operational tolerance to a fully MHC-mismatched cardiac

76 to demonstrate the ability of DST to induce operational tolerance to cardiac allografts in large ani

77 active T reg cells during the development of operational tolerance to donor alloantigens in vivo.

78 Operational tolerance to HLA-A, B, and DR mismatched org

79 rapamycin treatment failed to promote early operational tolerance to LT.

80 how that it is possible to create a state of operational tolerance to lung allografts even in the pre

81 In utero inoculation led to operational tolerance to the donor's major histocompatib

82 with a mean age of 15 years; 13 patients had operational tolerance (TOL), with complete immunosuppres

83 Eight (53%) achieved operational tolerance (TOL).

84 Operational tolerance was achieved with only 4 days of d

85 Operational tolerance was associated with time posttrans

86 d augmentation of expression was possible as operational tolerance was established to factor VIII wit

87 Operational tolerance was induced in hemiface allograft

88 ome kidney transplant recipients can achieve operational tolerance, we compared the expression profil

89 r histocompatibility complex peptide induces operational tolerance, whereas thymectomy abrogates this

90 Two of the 5 patients achieved operational tolerance with no clinical or histologic evi

91 or bone marrow (DBM) is shown here to induce operational tolerance with prolonged graft survival in t